Professor Nicholas Harvey, IOF President, lauded Dr. Chevalley for his unwavering commitment to the Foundation’s initiatives. Harvey emphasized Chevalley’s leadership as Vice-Chair of the governance board of the Capture the Fracture® programme, an initiative dedicated to the reduction of fracture risks worldwide through systematic post-fracture care coordination. Dr. Chevalley’s extensive involvement in the IOF Committee of Scientific Advisors and various scientific programs has been instrumental in shaping contemporary osteoporosis research and preventive strategies, highlighting his influential position in the international bone health community.

Dr. Chevalley’s academic journey reflects a profound dedication to osteology and geriatric medicine. Earning his medical degree from the University of Lausanne, he pursued doctoral studies at the University of Geneva, focusing his research on calcium supplementation and its impact on bone mineral density and fracture incidence among elderly populations. This work illuminated critical aspects of nutritional interventions in osteoporosis management, providing evidence-based guidance for clinical recommendations targeting older adults at high risk of fractures.

Upon completing postdoctoral research at Loma Linda University in California, Dr. Chevalley joined Geneva University Hospitals, where he assumed key roles including Head of the Geriatrics Liaison Unit and Consulting Physician in Bone Diseases. His multidisciplinary expertise encompasses the intersection of geriatrics and metabolic bone diseases, enabling him to contribute significantly to patient-centered approaches in fracture prevention and osteoporosis care. His clinical insights have informed both regional and international protocols for managing bone fragility.

As an internationally recognized authority on osteoporosis, Dr. Chevalley contributes to multiple high-profile advisory boards, including the IOF Committee of Scientific Advisors and the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO). His vice-chair position within the Capture the Fracture® programme’s governance structure underscores his leadership in promoting fracture liaison services (FLS), a systematic approach aimed at identifying and managing patients after fragility fractures to prevent subsequent fractures.

In addition to his organizational roles, Dr. Chevalley is a vital contributor to scientific literature, serving as Associate Editor for prestigious journals such as Osteoporosis International and Archives of Osteoporosis. His publication record, with over 8,000 citations, spans a broad spectrum of topics including the efficacy of fracture liaison services, bone health across the lifespan, and the complex relationships between nutrition, growth, and aging in skeletal homeostasis. His research continues to influence both clinical practice and health policy aimed at reducing the burden of musculoskeletal diseases.

Dr. Chevalley has been particularly active in promoting the development and implementation of fracture liaison services in Switzerland, collaborating with the Swiss Association Against Osteoporosis (ASCO). These services represent a paradigm shift in secondary fracture prevention, focusing on coordinated care pathways that integrate orthopedic care with osteoporosis assessment and treatment. His advocacy helps bridge gaps between acute fracture care and long-term bone health management, aiming to reduce recurrent fracture rates and associated morbidity.

The recognition of Dr. Chevalley’s contributions at WCO-IOF-ESCEO 2026, the world’s largest annual congress dedicated to bone, muscle, and joint diseases, reaffirms the critical importance of translational science in musculoskeletal health. The congress serves as an essential platform where researchers and clinicians converge to disseminate cutting-edge clinical research and explore therapeutic advancements in conditions such as osteoporosis, osteoarthritis, sarcopenia, and rare skeletal disorders.

Through his work, Dr. Chevalley exemplifies the integration of clinical expertise, research excellence, and organizational leadership necessary to tackle the complex challenges posed by musculoskeletal diseases. His efforts resonate beyond academia, influencing healthcare delivery systems worldwide and encouraging multidisciplinary collaboration to improve patient outcomes through evidence-based interventions.

The award reflects not only past achievements but also Dr. Chevalley’s ongoing commitment to innovation in fracture prevention and skeletal health. His involvement with global initiatives, coupled with his focus on geriatric populations and metabolic bone disease, positions him at the forefront of developing strategies that address aging-related bone loss and fracture risk reduction.

The IOF President’s Award bestowed upon Dr. Thierry Chevalley acknowledges a career dedicated to enhancing the understanding and clinical management of bone diseases, particularly osteoporosis, which remains a significant public health challenge globally. His intricate understanding of the biological mechanisms underpinning bone fragility and his advocacy for integrated care services underpin efforts to reduce the incidence and impact of fractures worldwide.

As the global population ages, the importance of experts like Dr. Chevalley in guiding policy and clinical practice cannot be overstated. His scientific contributions and leadership continue to shape the future of musculoskeletal health, aiming toward a world where fractures and their debilitating consequences are significantly diminished through innovation, education, and coordinated healthcare delivery.

Subject of Research: Osteoporosis, fracture prevention, fracture liaison services, bone health in geriatrics, effects of calcium supplementation on bone density

Article Title: International Osteoporosis Foundation Honors Dr. Thierry Chevalley with IOF President’s Award for Advancing Global Bone Health

News Publication Date: April 16, 2026

Web References:

• https://www.wco-iof-esceo.org/
• https://www.osteoporosis.foundation/

Keywords: Osteoporosis, fracture prevention, geriatrics, bone health, fracture liaison services, calcium supplementation, metabolic bone disorders, musculoskeletal diseases, aging, IOF President’s Award, Capture the Fracture®, clinical research, osteoporosis management

The research tackles a persistent problem in medical therapy: the non-specific effects of drugs. When medications are administered, they often impact a broad range of tissues, leading to systemic effects that can result in serious side effects. For instance, thousands of individuals in Switzerland alone suffer from severe drug-related reactions every year. The ability to activate treatments solely at their intended sites could revolutionize therapeutic approaches, particularly in treating diseases such as skin cancer.

The breakthrough technique that emerged from this research focuses on the activation of a specific protein involved in cell division, known as Plk1. Gotta and Winssinger aimed to cultivate a method that permits researchers to inhibit this protein selectively, facilitating a deeper understanding of its role in developmental biology. Their innovative strategy combines methods from both chemistry and biology to create a light-activated Plk1 inhibitor.

To achieve this, the researchers modified an existing Plk1 inhibitor molecule so that it became responsive to light. They incorporated a coumarin derivative—a compound found in certain plants— into the inhibitor, which effectively blocked the active site. The unique aspect of this design is that the inhibitor could be released from the coumarin’s hold with a straightforward light pulse. Thus, a simple flash of light could control the inhibitor’s activity at the desired location without affecting surrounding cells.

Yet another critical challenge was to ensure that the inhibitor remained fixed at the target location within the body. To address this, the researchers further modified the molecule by introducing a molecular anchor. This anchor is designed to detach only when exposed to light, allowing for precise spatial control. Consequently, the same light pulse could both activate and anchor the inhibitor to deactivate Plk1, halting cell division exactly where needed.

The ramifications of this research extend far beyond just understanding cell division. The developed system can potentially adapt to various other drug molecules, creating the possibility of activating treatments precisely where they are required in the body. The researchers envision that in the future, a simple laser could target diseased tissues, sparing healthy cells and limiting potential side effects. This level of precision would mark a significant leap forward in the quest for more effective and safer medical treatments.

As the scientific community further explores this technology, the potential applications appear to be limitless. Ultimately, the innovative control of molecule activity could lead to substantial advancements in both basic research and applied medical treatments. It might open new pathways for the development of therapies that are tailored to deactivate problematic proteins only when and where they are needed. Utilizing light as a control mechanism provides an elegant solution to the issue of systemic medication effects.

The interdisciplinary collaboration between chemists and biologists at UNIGE exemplifies the importance of cross-disciplinary research in addressing contemporary health challenges. As noted by Gotta, the research initiated from a method-driven question, focusing on how to specifically inhibit Plk1 to better discern its functional role within an organism. This interdisciplinary approach rich in collaboration and practical testing has yielded results that have the potential to influence numerous fields, including pharmacology, genetics, and cellular biology.

This research not only highlights the capabilities of sophisticated light-based control systems but also prompts a reevaluation of conventional drug delivery methods. The implications of achieving precise molecular modulation could reshape our understanding of interactions at the cellular level, ultimately paving the way for next-generation therapies with reduced side effects.

Indeed, this research showcases the significant advancements being made within the life sciences, encouraging scientists to seek further innovations that can enhance our control over biological systems. As researchers continue to refine and expand the system’s applications, the hope is that we will soon witness tangible improvements in clinical strategies that lead to better patient outcomes across various therapeutic areas.

In conclusion, the work of the UNIGE team represents a significant milestone in the quest for precise and effective medical treatments. By seamlessly merging the disciplines of chemistry and biology, they have opened a new frontier in our capacity to control molecular activity with unparalleled accuracy using light. This pioneering approach could redefine how treatments are developed and administered in the realm of medicine, potentially revolutionizing how we address complex biological challenges in the future.

Subject of Research: Cells
Article Title: “Spatio-temporal control of mitosis using light via a Plk1 inhibitor caged for activity and cellular permeability”
News Publication Date: 19-Feb-2025
Web References: http://dx.doi.org/10.1038/s41467-025-56746-5
References: Nature Communications
Image Credits: © Gotta lab – UNIGE

Keywords

Light-activated drugs, Plk1 inhibitor, University of Geneva, medical treatments, targeted therapy, cellular biology, precise activation, side effects reduction, interdisciplinary research